Biomark Diagnostics Inc (CSE:BUX)

0.5200 -0.0300 (-5.45%)

Delayed Quote Updated: 10:03 AM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biomark Diagnostics Inc

< Previous 1 2 Next >

BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences

September 21, 2026

Vancouver, British Columbia--(Newsfile Corp. - September 21, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or...

Via Newsfile

BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy

August 25, 2026

Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),...

Via Newsfile

Topics Artificial Intelligence

BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day

July 31, 2026

Vancouver, British Columbia--(Newsfile Corp. - July 31, 2026) - As the global healthcare community unites on August 1st to observe...

Via Newsfile

Topics Death

BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test

June 23, 2026

Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),...

Via Newsfile

Topics Intellectual Property

BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform

June 09, 2026

Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),...

Via Newsfile

Topics Intellectual Property

BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum

April 14, 2026

Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),...

Via Newsfile

Topics Death

BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology

January 15, 2026

Vancouver, British Columbia--(Newsfile Corp. - January 15, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a...

Via Newsfile

Topics Artificial Intelligence

BioMark: 2025 Achievements & 2026 Vision

December 31, 2025

Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),...

Via Newsfile

BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors

December 30, 2025

Vancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),...

Via Newsfile

Topics Artificial Intelligence

BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program

December 23, 2025

Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading...

Via Newsfile

BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala

December 01, 2025

Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a...

Via Newsfile

Topics Artificial Intelligence

BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy

November 12, 2025

Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CSE: BUX)...

Via Newsfile

Topics Artificial Intelligence

BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial

October 07, 2025

Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer...

Via Newsfile

BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy

September 29, 2025

Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading...

Via Newsfile

Topics Intellectual Property

BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership

August 12, 2025

Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer...

Via Newsfile

BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement

December 29, 2023

Vancouver, British Columbia--(Newsfile Corp. - December 29, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"...

Via Newsfile

BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay

December 04, 2023

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF)...

Via Newsfile

Topics Intellectual Property

BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term

November 28, 2023

Vancouver, British Columbia--(Newsfile Corp. - November 28, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"...

Via Newsfile

BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives

November 14, 2023

Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark")...

Via Newsfile

Topics Artificial Intelligence

BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test

November 07, 2023

Vancouver, British Columbia and Quebec City, Quebec--(Newsfile Corp. - November 7, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B)...

Via Newsfile

BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium

October 24, 2023

Vancouver, British Columbia--(Newsfile Corp. - October 24, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark")...

Via Newsfile

BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team

August 30, 2023

Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ...

Via Newsfile

Topics Intellectual Property

Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay

August 08, 2023

Vancouver, British Columbia--(Newsfile Corp. - August 8, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"),...

Via Newsfile

Topics Intellectual Property

BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting

June 05, 2023

Vancouver, British Columbia--(Newsfile Corp. - June 5, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ...

Via Newsfile

BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay

May 31, 2023

Vancouver, British Columbia--(Newsfile Corp. - May 31, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark")...

Via Newsfile

Topics Death Intellectual Property

BioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

May 03, 2023

Vancouver, British Columbia--(Newsfile Corp. - May 3, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark")...

Via Newsfile

BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine Tumors

March 16, 2023

Vancouver, British Columbia--(Newsfile Corp. - March 16, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark")...

Via Newsfile

Biomark Receives Funding Supporting Research and Development Project for Cancer Treatment Monitoring

February 07, 2023

Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF)...

Via Newsfile

BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch

January 11, 2023

Vancouver, British Columbia--(Newsfile Corp. - January 11, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or...

Via Newsfile

Topics Climate Change

BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer

November 30, 2021

Vancouver, British Columbia--(Newsfile Corp. - November 30, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark")...

Via Newsfile

Topics Artificial Intelligence Death

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.